Info

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company focuses on the development of antivirals for the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis C and the development of antibacterials for the treatment of serious hospital-based bacterial infections. The Company has advanced its lead drug candidate, elvucitabine for the treatment of HIV infection, into phase II clinical trials. In addition, it is advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, and ACH-702 for the treatment of serious hospital-based bacterial infections. Achillion is also developing a series of inhibitors of HCV protease in early preclinical assessment.(Source: 10-K)